Work

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Year: 2005

Type: article

Source: Cancer Cell

DOI: 10.1016/j.ccr.2005.01.007

Institutions: Dana-Farber Cancer Institute, Novartis (Switzerland), Novartis Institutes for BioMedical Research, Brigham and Women's Hospital, Boston Children's Hospital

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: Therapeutic Mechanisms in Chronic Myelogenous Leukemia, G2852253759, G3715452210, G409126305, G4822109355, Abnormalities/Signal Transduction/Hematopoietic Disease, Development of Novel Therapeutic Strategies in Human Leukemias

OpenAlex ID: W2124196948

FWCI: 59.91

Cites: 69

Cited by: 1,492

Related to: 10